Business Description
Boston Scientific Corp
NAICS : 339112
SIC : 3841
ISIN : US1011371077
Share Class Description:
BSX: Ordinary SharesTotal Employee Number:
59,000Compare
Compare
Traded in other countries / regions
BSX.USA0HOY.UKBSX.MexicoBSX.GermanyB1SX34.BrazilBSXC.Austria1BSX.ItalyBSX.Switzerland Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1992-05-18Description
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | 2.01 | |||||
Interest Coverage | 11.5 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 3.3 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.1 | |||||
3-Year EBITDA Growth Rate | 21.4 | |||||
3-Year EPS without NRI Growth Rate | 21.4 | |||||
3-Year FCF Growth Rate | 53.1 | |||||
3-Year Book Growth Rate | 10 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.39 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.96 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.1 | |||||
9-Day RSI | 45.19 | |||||
14-Day RSI | 40.48 | |||||
3-1 Month Momentum % | -21.77 | |||||
6-1 Month Momentum % | -50.49 | |||||
12-1 Month Momentum % | -53.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.9 | |||||
Quick Ratio | 1.22 | |||||
Cash Ratio | 0.32 | |||||
Days Inventory | 168.88 | |||||
Days Sales Outstanding | 50.6 | |||||
Days Payable | 60.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -0.71 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.16 | |||||
Operating Margin % | 19.92 | |||||
Net Margin % | 17.29 | |||||
EBITDA Margin % | 26.65 | |||||
FCF Margin % | 16 | |||||
OCF Margin % | 21.06 | |||||
ROE % | 15.09 | |||||
ROA % | 8.39 | |||||
ROIC % | 10.43 | |||||
3-Year ROIIC % | 24.29 | |||||
ROC (Joel Greenblatt) % | 66.79 | |||||
ROCE % | 10.97 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.73 | |||||
Forward PE Ratio | 13.33 | |||||
PE Ratio without NRI | 14.44 | |||||
Shiller PE Ratio | 35.53 | |||||
Price-to-Owner-Earnings | 19.97 | |||||
PEG Ratio | 0.6 | |||||
PS Ratio | 3.22 | |||||
PB Ratio | 2.57 | |||||
Price-to-Tangible-Book | 248.72 | |||||
Price-to-Free-Cash-Flow | 20.32 | |||||
Price-to-Operating-Cash-Flow | 15.42 | |||||
EV-to-EBIT | 18.63 | |||||
EV-to-Forward-EBIT | 18.54 | |||||
EV-to-EBITDA | 13.9 | |||||
EV-to-Forward-EBITDA | 13.14 | |||||
EV-to-Revenue | 3.7 | |||||
EV-to-Forward-Revenue | 3.54 | |||||
EV-to-FCF | 23.15 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Projected-FCF | 1.43 | |||||
Price-to-DCF (Earnings Based) | 0.87 | |||||
Price-to-DCF (FCF Based) | 0.65 | |||||
Price-to-Median-PS-Value | 0.6 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.73 | |||||
Price-to-Graham-Number | 12.65 | |||||
Earnings Yield (Greenblatt) % | 5.37 | |||||
FCF Yield % | 4.96 | |||||
Forward Rate of Return (Yacktman) % | 22.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BSX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Boston Scientific Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20,615 | ||
| EPS (TTM) ($) | 2.39 | ||
| Beta | 0.5849 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.41 | ||
| Volatility % | 26.08 | ||
| 14-Day RSI | 40.48 | ||
| 14-Day ATR ($) | 1.536284 | ||
| 20-Day SMA ($) | 44.9825 | ||
| 12-1 Month Momentum % | -53.46 | ||
| 52-Week Range ($) | 42.25 - 109.5 | ||
| Shares Outstanding (Mil) | 1,486.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Boston Scientific Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Boston Scientific Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-22 08:00 | In 104 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 103 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 18 days | ||
| Bernstein\'s 42nd Annual Strategic Decisions Conference | 2026-05-27 08:00 | 57.64 (-0.19%) | ||
| General meeting for 2026 | 2026-04-30 08:00 | 57.15 (-0.97%) | ||
| First quarter earnings conference call for 2026 | 2026-04-22 08:00 | 59.52 (-2.01%) | ||
| First quarter earnings results for 2026 | 2026-04-22 | 59.52 (-2.01%) | ||
| 75th Annual Scientific Session of the American College of Cardiology | 2026-03-28 18:30 | 69.17 (-1.23%) | ||
| TD Cowen\'s 46th Annual Health Care Conference | 2026-03-03 09:10 | 76.22 (-0.08%) |
Show
Entries
Boston Scientific Corp Frequently Asked Questions
What is Boston Scientific Corp(BSX)'s stock price today?
The current price of BSX is $44.77. The 52 week high of BSX is $109.50 and 52 week low is $42.25.
When is next earnings date of Boston Scientific Corp(BSX)?
The next earnings date of Boston Scientific Corp(BSX) is 2026-07-29.
Does Boston Scientific Corp(BSX) pay dividends? If so, how much?
Boston Scientific Corp(BSX) does not pay dividend.
Press Release
Articles on Boston Scientific Corp
Headlines
See More- 1
Jun 28, 2026
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Seeking Alpha • 8:05am
Jun 25, 2026
Portfolio check: The biggest SA Quant downgrades over the past week
Seeking Alpha • 10:51am
Jun 14, 2026
Notable healthcare headlines for the week: GSK, Parabilis Medicines, and Novo Nordisk in focus
Seeking Alpha • 8:05am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers